ResearcherSecond Military Medical UniversityActive in the last 2 years
Jian Yang
Matched on ORCID iD 0000-0003-4721-7744; OpenAlex author ID A5032721803. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2019: 2 papers · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper
Papers 6
- SERTAD4-AS1 suppresses pancreatic cancer progression by stabilizing SERTAD4 and inhibiting the Notch1 pathway. Co-author DOI 10.1016/j.gendis.2025.101870↗
- Comment on "Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression". Co-author DOI 10.4251/wjgo.v15.i2.368↗
- Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer. Co-author DOI 10.1007/s00259-022-05729-5↗
- Development and validation of a tissue-based DNA methylation risk-score model to predict the prognosis of surgically resected pancreatic cancer patients. Co-author DOI 10.21037/gs-22-517↗
- A Panel of Three Biomarkers Identified by iTRAQ for the Early Diagnosis of Pancreatic Cancer. Co-author DOI 10.1002/prca.201800195↗
- DcR3 promotes proliferation and invasion of pancreatic cancer via a DcR3/STAT1/IRF1 feedback loop. Co-author PMID 31911850↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jian Zhou · 3 shared papers, 2019–2026 · strength 0.48
- Paper SERTAD4-AS1 suppresses pancreatic cancer progression by stabilizing SERTAD4 and inhibiting the Notch1 pathway. DOI 10.1016/j.gendis.2025.101870↗
- Paper A Panel of Three Biomarkers Identified by iTRAQ for the Early Diagnosis of Pancreatic Cancer. DOI 10.1002/prca.201800195↗
- Paper DcR3 promotes proliferation and invasion of pancreatic cancer via a DcR3/STAT1/IRF1 feedback loop. PMID 31911850↗
- Haoran Li · 2 shared papers, 2022–2026 · strength 0.45
- Paper SERTAD4-AS1 suppresses pancreatic cancer progression by stabilizing SERTAD4 and inhibiting the Notch1 pathway. DOI 10.1016/j.gendis.2025.101870↗
- Paper Development and validation of a tissue-based DNA methylation risk-score model to predict the prognosis of surgically re… DOI 10.21037/gs-22-517↗
- Yuchen Tang · 2 shared papers, 2022–2026 · strength 0.45
- Paper SERTAD4-AS1 suppresses pancreatic cancer progression by stabilizing SERTAD4 and inhibiting the Notch1 pathway. DOI 10.1016/j.gendis.2025.101870↗
- Paper Development and validation of a tissue-based DNA methylation risk-score model to predict the prognosis of surgically re… DOI 10.21037/gs-22-517↗
- Bin Yi · 2 shared papers, 2022–2026 · strength 0.45
- Paper SERTAD4-AS1 suppresses pancreatic cancer progression by stabilizing SERTAD4 and inhibiting the Notch1 pathway. DOI 10.1016/j.gendis.2025.101870↗
- Paper Development and validation of a tissue-based DNA methylation risk-score model to predict the prognosis of surgically re… DOI 10.21037/gs-22-517↗
- Yijun Wei · 2 shared papers, 2019–2026 · strength 0.39
- Ying Liu · 1 shared paper, 2023 · strength 0.31
- Shi Liu · 1 shared paper, 2023 · strength 0.31
- Jun Yao · 1 shared paper, 2026 · strength 0.29
- Zixiang Zhang · 2 shared papers, 2019–2022 · strength 0.25
- Dechun Li · 2 shared papers, 2019 · strength 0.19
- Dongming Zhu · 2 shared papers, 2019 · strength 0.19
- Jie Wang · 1 shared paper, 2022 · strength 0.16
- Ye Li · 1 shared paper, 2022 · strength 0.16
- Tao Wang · 1 shared paper, 2022 · strength 0.15
- Guorong Jia · 1 shared paper, 2022 · strength 0.15
- Changjing Zuo · 1 shared paper, 2022 · strength 0.15
- Chao Cheng · 1 shared paper, 2022 · strength 0.15
- Zeyu Zhang · 1 shared paper, 2022 · strength 0.15
- Kai Cao · 1 shared paper, 2022 · strength 0.15
- Zixiang Zhang · 1 shared paper, 2019 · strength 0.10
- Jun Yao · 1 shared paper, 2019 · strength 0.10
- Xing Wu · 1 shared paper, 2019 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.